PB0717 - Urological cancer patients display an increase in markers of hypercoagulability and inflammation

Monday, June 26, 2023

18:30 – 19:30 ET

Room: Exhibition

Presenting Author(s)

Raquel Herranz, MSc (she/her/hers)

PhD Candidate
Hemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain
Valencia, Comunidad Valenciana, Spain

Co-Author(s)

Julia Oto

Postdoctoral Researcher
Hemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
FC

Fernando Cana

Laboratory Technician
Hemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
MC

Maria Castaño

Researcher
Hemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
IA

Isabel Aleman-Cabrera

PhD Student
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
AM

Antonio Moscardo

Postdoctoral Researcher
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain; Thrombosis and Haemostasis Unit, Haematology Service, La Fe University and Polytechnic Hospital, Valencia, Spain.
Valencia, Comunidad Valenciana, Spain
EP

Emma Plana

Postdoctoral Researcher
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain; Angiology and Vascular Surgery Service, La Fe University and Polytechnic Hospital, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
LG

Luis Gomez-Cambronero

Medical doctor
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain; Thrombosis and Haemostasis Unit, Haematology Service, La Fe University and Polytechnic Hospital, Valencia, Spain.
Valencia, Comunidad Valenciana, Spain
JA

Jose Vicente Amaya

Medical doctor
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain; Orthopaedics and Traumatology Service. La Fe University and Polytechnic Hospital, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
CV

Cesar D. Vera-Donoso

Medical doctor
Department of Urology, La Fe University and Polytechnic Hospital, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
PM

Pau Martínez

Medical doctor
Department of Urology, Manises Hospital, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
MM

Manuel Martínez-Sarmiento

Medical doctor
Department of Urology, La Fe University and Polytechnic Hospital, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
SB

Santiago Bonanad

Head of Thrombosis and Hemostasis Unit
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain; Thrombosis and Haemostasis Unit, Haematology Service, La Fe University and Polytechnic Hospital, Valencia, Spain
Valencia, Comunidad Valenciana, Spain
PM

Pilar Medina

PI
Hemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute Hospital La Fe, Valencia, Spain
Valencia, Comunidad Valenciana, Spain

Background: Not only cancer growth develops a subclinical hypercoagulable state, but also hypercoagulability is a key contributor in cancer progression beyond cancer-associated thrombosis. Increasing evidence shows that coagulation proteins have multiple functions in tumor progression and metastasis, although current knowledge is rather limited. Urological tumors are not an exception.

Aims: To analyze the dysregulation of an extensive profile of hemostatic proteins and analytical variables in urological cancer patients.

Methods: We recruited 70 cancer patients before surgery (38 bladder, 20 prostate, 12 renal) and 42 healthy controls. We quantified a profile of 81 variables: 25 blood biochemistry parameters, 24 parameters of full hemogram, 8 parameters of hemostasis and 24 markers of coagulation, natural anticoagulants and fibrinolysis (fibrinogen, D-dimer, FVIII, FVII, FXIII, FVW, protein C, protein S, antithrombin, plasminogen, PAI-1, α2-antiplasmin, ADAMTS13).

Results: Compared to controls, urological cancer patients showed a significant increase in C reactive protein (P=0.010), leucocytes (0.007), neutrophils (0.010), monocytes (0.039), eosinophils % (0.005), TTPA (0.0332), D-dimer (0.039), fibrinogen (0.010), creatinine (0.025), ApoB/ApoA1 (0.03904), uric acid (0.021) and triglycerides (0.031); and a decrease in and α2-antiplasmin (0.017), ApoA1 (0.0001) and CHCM (0.020). Unlike previous studies, no differences in FVIII levels were evidenced. Attending to the different cancer types studied, bladder cancer patients displayed the greatest differences in variables, whereas renal cancer patients had the highest PAI-1 levels and prostate cancer the highest FXIII. No differences were observed in natural anticoagulants protein C, protein S or antithrombin.

Conclusion(s): Active urological cancer patients display an increase in blood cell counts and in markers of hypercoagulability and inflammation. The activation of a subclinical hypercoagulable state differs among cancer types, probably contributing differently to tumorigenesis. These markers could be useful in follow-up. Further studies in larger cancer cohorts are needed to validate our findings. ISCIII-FEDER (PI20/00075, FI21/00171), GVA-CIACIF/2021/192 and SETH.